tbuckley/cabot-search huggingface dataset:
Late relapses in Hodgkin's disease.
Authors: M. Provencio-Pulla, A. Sánchez, B. Cantos, J. Gasent Blesa, M. Mendez, C. Maximiano, R. Cubedo, F. Bonilla, L. Galan, M. Huelves
Journal: Journal of Clinical Oncology (2010)

e18537 Background: Survival in Hodgkin's Disease (HD) has significantly increased. There is no consensus on the definition of late relapse in Hodgkin's Disease. No consistent prognostic factors for the development of late relapse have been identified. There are very few studies on this situation.We analyze late relapses, beyond five years, on how they are diagnosed, their behavior and the characteristics associated with them. Methods: We reviewed the database of patients with HD in our hospital (1967-2005). To obtain our study population, we have reviewed the database of patients with Hodgkin's Disease treated in our hospital between the years 1967 and 2005 and selected those who had relapses of their disease after achieving complete remission with the first line of treatment. Patients were prospectively followed up from their diagnosis every 3 months during the first 2 years, every 6 months between 2 and 5 years, and annually from the fifth year on. Results: We studied 534 with HD. Disease-free survival in this series was 83% at two years and 68% at 5 years, although without reaching the median follow-up. We found 150 relapses (27%), 30 of which occurred five years after the end of treatment. The relapses were detected in a scheduled appointment in 16 (54%) asymptomatic patients. 7/30 patients had a different histological type. There were no statistically significant differences in survival between those patients with a late relapse and new remission and those who never relapsed. Conclusions: Long-term survival was not significantly different in relapsed patients with remission after treatment from that of patients never relapsed. Late relapses in Hodgkin's Disease needs to be analyzed separately, perhaps linked to the biological behavior of the tumor. We need to individualize treatment according to location of relapse and maintain active follow-ups to detect late and recoverable relapses No significant financial relationships to disclose.
P1-194: Individual screening of lung cancer in france: results of EDIFICE study
Authors: Jean-François Morere, Xavier Pivot, Olivier Rixe, François Eisinger, Sylvie Dolbeault, Anne Calazel Benque, Laurent Cals, Yvan Coscas, Claire Roussel, Jean-Yves Blay
Journal: Journal of Thoracic Oncology (2007)
Molecular or Metabolic Reprograming: What Triggers Tumor Subtypes?
Authors: Katherine Eason, Anguraj Sadanandam
Journal: Cancer Research (2016)

Abstract Tumor heterogeneity is reflected and influenced by genetic, epigenetic, and metabolic differences in cancer cells and their interactions with a complex microenvironment. This heterogeneity has resulted in the stratification of tumors into subtypes, mainly based on cancer-specific genomic or transcriptomic profiles. Subtyping can lead to biomarker identification for personalized diagnosis and therapy, but stratification alone does not explain the origins of tumor heterogeneity. Heterogeneity has traditionally been thought to arise from distinct mutations/aberrations in “driver” oncogenes. However, certain subtypes appear to be the result of adaptation to the disrupted microenvironment caused by abnormal tumor vasculature triggering metabolic switches. Moreover, heterogeneity persists despite the predominance of single oncogenic driver mutations, perhaps due to second metabolic or genetic “hits.” In certain cancer types, existing subtypes have metabolic and transcriptomic phenotypes that are reminiscent of normal differentiated cells, whereas others reflect the phenotypes of stem or mesenchymal cells. The cell-of-origin may, therefore, play a role in tumor heterogeneity. In this review, we focus on how cancer cell–specific heterogeneity is driven by different genetic or metabolic factors alone or in combination using specific cancers to illustrate these concepts. Cancer Res; 76(18); 5195–200. ©2016 AACR.
Asthma quality of life and control after sinus surgery in patients with chronic rhinosinusitis
Authors: R. J. Schlosser, T. L. Smith, J. Mace, Z. M. Soler
Journal: Allergy (2016)

Patients with chronic rhinosinusitis (CRS) often have comorbid asthma. Prior studies have not examined the impact of CRS or endoscopic sinus surgery (ESS) upon asthma quality of life (QOL) and asthma control using validated outcome metrics.Patients with CRS, both with and without polyps, and comorbid asthma completed the Mini Asthma QOL Questionnaire (miniAQLQ) and Asthma Control Test (ACT) at baseline and 6 months postoperatively as part of a multi-institutional, prospective study.Baseline metrics were available on 86 patients. Patients undergoing ESS reported improved miniAQLQ [0.5 (SD ±1.1), 95% CI: 0.2-0.7; P = 0.002] and ACT scores [1.3 (±4.1), 95% CI: 0.2-2.4; P = 0.025]. Uncontrolled baseline asthma (ACT < 20) was present in 51% of patients undergoing ESS. In uncontrolled patients, ESS resulted in a minimal clinically important difference 57% of the time for miniAQLQ scores (≥0.5 points) and 50% of the time for ACT scores (≥3.0 points). After adjustment with linear regression, baseline miniAQLQ scores were worse in patients with comorbid allergy (P = 0.045) and chronic obstructive pulmonary disease (COPD; P = 0.015). Adjusted baseline ACT scores were worse in patients with COPD (P = 0.004). Covariates associated with changes in miniAQLQ scores after ESS were pre-operative corticosteroid dependency (P = 0.011) and change in total SNOT-22 score (P = 0.010). Covariate associated with significantly less improvement in ACT scores was obstructive sleep apnea (P = 0.016).Patients with CRS often present with uncontrolled asthma, and ESS improves both miniAQLQ and ACT. Approximately half of patients with uncontrolled asthma improve after ESS, yet there are few CRS-specific factors associated with asthma QOL or control or ESS outcomes.
P1-131: A patient with recurrent giant mediastinal liposarcoma
Authors: Turgut Isitmangil, Habil Tunc, Bayram A. Ozuslu, Rauf Gorur, Nurettin Yiyit, Akin Yildizhan, Fatih Candas, Oryal Erdik, Sefa Selcuk, Hakan Cermik
Journal: Journal of Thoracic Oncology (2007)
Age-specific trends of survival in metastatic breast cancer: Data from a population-based cancer registry in Stockholm, Sweden.
Authors: T. Foukakis, T. Fornander, T. Lekberg, H. Hellborg, J. Adolfsson, J. Bergh
Journal: Journal of Clinical Oncology (2010)

1058 Background: Treatment of metastatic breast cancer (MBC) has greatly evolved during the last decades but it is largely unknown whether this has lead to an improvement of survival in the general MBC population. Methods: Based on the regional, population-based breast cancer registry, we identified 5,463 patients diagnosed with MBC (locoregional disease excluded) in Stockholm County during the years of 1979-2004. Patients were divided into five cohorts depending on the year of first diagnosis of MBC and overall survival was compared across the cohorts after adjustment for differences in other prognostic factors using a stratified multivariate Cox regression model. Additionally, relative survival ratios were calculated as a measure of excess mortality in MBC compared to the corresponding general population in each time period. Results: A statistically significant trend of better survival over time was demonstrated for patients 60 years of age or younger at the time of MBC diagnosis (p<0.001, by log-rank test for trend), but not for patients older than 60 years (p=0.12) or for the whole MBC population (p=0.14). When adjusted for potential confounders, the survival of patients under 60 years diagnosed with MBC was significantly improved in the 2000-2004 cohort (p<0.001, hazard ratio (HR) > 0.7, 95% confidence interval (CI)= 0.58-0.84), corresponding to a clinically significant increase of median survival with more than 3 months and an absolute increase of 5-year survival with 8% or more compared to previous cohorts. No statistically significant survival differences were seen for the older subpopulation and among previous calendar periods. The findings were corroborated by the relative survival analysis that indicated a 31% decreased mortality for the younger subpopulation in the 2000-2004 cohort (p<0.001). Conclusions: We demonstrate a clinically and statistically significant improvement in the survival of MBC population during the past decades, restricted to patients under 60 years of age and mainly occurring after the year 2000. For older patients with MBC, survival remained essentially unchanged during the same period. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Affybodies, Amgen, Asklepios BioPharmaceutical, AstraZeneca, GlaxoSmithKline, Onyx/Bayer, sanofi-aventis Asklepios BioPharmaceutical, AstraZeneca, Pfizer, Roche Merck, Pfizer, Roche
Abstract 17766: PET Imaging With 68Ga-DOTATATE Can Detect High-risk Carotid and Coronary Atherosclerotic Lesions
Authors: Jason M Tarkin, Francis R Joshi, Nicholas R Evans, Ashley M Groves, Deepa Gopalan, Roie Manavaki, Patrick J Kirkpatrick, Patrick A Coughlin, Paul Hayes, John R Buscombe, Tim D Fryer, Martin R Bennett, Anthony P Davenport, Elizabeth A Warburton, James H Rudd
Journal: Circulation (2015)

Introduction: Up-regulation of somatostatin receptor subtype-2 (SST2) has been observed on the cell surface of activated macrophages, where it can potentially be exploited as a molecular imaging target to identify high-risk plaque. Hypothesis: We tested the hypothesis that SST2 vascular PET imaging with 68Ga-DOTATATE can reveal high-risk plaque in patients with atherosclerosis, and compared with 18F-FDG. Methods: Prospective sequential 68Ga-DOTATATE and 18F-FDG PET imaging plus CT angiography was performed in 39 patients with atherosclerosis. Results: A total of 36 carotid arteries and 40 coronary plaques were analyzed. Mean age 69.5 ± 9.5 yrs, 76.9% male. Median (IQR) 68Ga-DOTATATE TBRmax was significantly higher in recently symptomatic carotid arteries compared to: 1) the contralateral side [p=0.0013], 2) stable carotid plaques [p&lt;0.0001] and 3) normal carotid arteries [p&lt;0.0001] Figs A and B. 18F-FDG TBRmax was also higher on the symptomatic side [1.60 (1.44-1.88) vs. 1.56 (1.31-1.78), p=0.0024]. Unlike 18F-FDG, myocardial 68Ga-DOTATATE binding was sufficiently low to allow coronary artery analysis in all patients. Culprit coronary plaques imaged 33 (21-62) days post-ACS had higher 68Ga-DOTATATE TBRmax compared to both stable stented plaques [p = 0.04] and stable calcific plaques [p &lt;0.0001]; however the highest signal occurred in relation to soft lipid-rich plaques. Conclusion: Measuring vascular inflammation with SST2 PET is feasible and differentiates high and low risk lesions. High target specificity, low myocardial binding and generator production offer potential advantages of 68Ga-DOTATATE over 18F-FDG and other tracers for imaging atherosclerosis.
C9-05: Clinicopathologic features and oncologic behaviors of the T1-sized lung cancer
Authors: Hyeong Ryul Kim, Sang Cheol Lee, Gwan Woo Ku, Chang Hyun Kang, Young Tae Kim, Sanghoon Jheon, Sook Whan Sung, Joo Hyun Kim, Jin-Haeng Chung
Journal: Journal of Thoracic Oncology (2007)
TreeScaper: Visualizing and Extracting Phylogenetic Signal from Sets of Trees
Authors: Wen Huang, Guifang Zhou, Melissa Marchand, Jeremy R. Ash, David Morris, Paul Van Dooren, Jeremy M. Brown, Kyle A. Gallivan, Jim C. Wilgenbusch
Journal: Molecular Biology and Evolution (2016)

Modern phylogenomic analyses often result in large collections of phylogenetic trees representing uncertainty in individual gene trees, variation across genes, or both. Extracting phylogenetic signal from these tree sets can be challenging, as they are difficult to visualize, explore, and quantify. To overcome some of these challenges, we have developed TreeScaper, an application for tree set visualization as well as the identification of distinct phylogenetic signals. GUI and command-line versions of TreeScaper and a manual with tutorials can be downloaded from https://github.com/whuang08/TreeScaper/releases. TreeScaper is distributed under the GNU General Public License.
P2-308: A bi-weekly administration of gemcitabine and docetaxel in patients with non-small cell lung cancer
Authors: Takayuki Shiina, Ryoichi Kondo, Kazuo Yoshida, Keiichiro Takasuna, Takeshi Yamanda, Tomonobu Koizumi, Keishi Kubo, Tsutomu Hachiya, Seiichiro Eda, Jun Amano
Journal: Journal of Thoracic Oncology (2007)
Individual and Joint Effects of Early-Life Ambient PM2.5 Exposure and Maternal Prepregnancy Obesity on Childhood Overweight or Obesity
Authors: Guangyun Mao, Rebecca Massa Nachman, Qi Sun, Xingyou Zhang, Kirsten Koehler, Zhu Chen, Xiumei Hong, Guoying Wang, Deanna Caruso, Geng Zong, Colleen Pearson, Hongkai Ji, Shyam Biswal, Barry Zuckerman, Marsha Wills-Karp, Xiaobin Wang
Journal: Environmental Health Perspectives (2016)

Background: Although previous studies suggest that exposure to traffic-related pollution during childhood increases the risk of childhood overweight or obesity (COWO), the role of early life exposure to fine particulate matter (aerodynamic diameter &lt;2.5μm; PM2.5) and its joint effect with the mother's prepregnancy body mass index (MPBMI) on COWO remain unclear. Objectives: The present study was conducted to examine the individual and joint effects of ambient PM2.5 exposures and MPBMI on the risk of COWO. Methods: We estimated exposures to ambient PM2.5 in utero and during the first 2 y of life (F2YL), using data from the U.S. Environmental Protection Agency’s (EPA's) Air Quality System matched to residential address, in 1,446 mother–infant pairs who were recruited at birth from 1998 and followed up prospectively through 2012 at the Boston Medical Center in Massachusetts. We quantified the individual and joint effects of PM2.5 exposure with MPBMI on COWO, defined as the child's age- and sex-specific BMI z-score ≥85th percentile at the last well-child care visit between 2 and 9 y of age. Additivity was assessed by estimating the reduced excess risk due to interaction. Results: Comparing the highest and lowest quartiles of PM2.5, the adjusted relative risks (RRs) [95% confidence intervals (CIs)] of COWO were 1.3 (95% CI: 1.1, 1.5), 1.2 (95% CI: 1.0, 1.4), 1.2 (95% CI: 1.0, 1.4), 1.3 (95% CI: 1.1, 1.6), 1.3 (95% CI: 1.1, 1.5) and 1.3 (1.1, 1.5) during preconception; the first, second, and third trimesters; the entire period of pregnancy; and F2YL, respectively. Spline regression showed a dose–response relationship between PM2.5 levels and COWO after a threshold near the median exposure (10.46μg/m3–10.89μg/m3). Compared with their counterparts, children of obese mothers exposed to high levels of PM2.5 had the highest risk of COWO [RR≥2.0, relative excess risk due to interaction (RERI) not significant]. Conclusions: In the present study, we observed that early life exposure to PM2.5 may play an important role in the early life origins of COWO and may increase the risk of COWO in children of mothers who were overweight or obese before pregnancy beyond the risk that can be attributed to MPBMI alone. Our findings emphasize the clinical and public health policy relevance of early life PM2.5 exposure. https://doi.org/10.1289/EHP261
GPs need more support to help young people with mental health problems, review finds
Authors: Jacqui Wise
Journal: BMJ (2016)

Significant barriers prevent primary care practitioners from effectively supporting children and adolescents with mental health problems, says a systematic review published in the British Journal of General Practice .1

The review said that the worldwide prevalence of mental health problems in children and adolescents has been estimated at 13.4% but that only a minority benefit from early detection and effective treatment. Considerable barriers include a lack of specialist providers and resources, lengthy …
P3-136: A Phase II study of XL647 in non-small cell lung cancer (NSCLC) patients enriched for presence of EGFR mutations
Authors: Naiyer Rizvi, Mark Kris, Vincent Miller, Christopher Azzoli, Lee Krug, Sara Bekele, Ruth Chaplen, John Ruckdeschel, Shirish Gadgeel
Journal: Journal of Thoracic Oncology (2007)
Improved Glycemic Control in Diabetic Patients Treated with Recombinant Human Erythropoietin.
Authors: Odelia Katz, Nataliya Golishevski, Howard S. Oster, Lilach Lifshitz, Sari Prutchi-Sagiv, Michael Hoffman, Moshe Mittelman, Drorit Neumann
Journal: Blood (2006)
Impact of Cost-Sharing Mechanisms on Patient-Borne Medication Costs
Authors: David J. T. Campbell, Lesley J. J. Soril, Fiona Clement
Journal: JAMA Internal Medicine (2016)

This simulated analysis of cost-sharing in member nations of the Organisation for Economic Co-operation and Development found a large variation in costs borne by patients, often dependent on age, comorbidities, and socioeconomic status.
Jean Louis-Alibert—Physician, Teacher, Pioneer
Authors: Richa Taneja, Eric Laurent Maranda, Omar G. Jarrett, Robert Heifetz, Shahjahan Shareef, Joaquin J. Jimenez
Journal: JAMA Dermatology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
Can Interim 18F-FDG PET or Diffusion-Weighted MRI Predict End-of-Treatment Outcome in FDG-Avid MALT Lymphoma After Rituximab-Based Therapy?
Authors: Marius E. Mayerhoefer, Georgios Karanikas, Kurt Kletter, Barbara Kiesewetter, Michael Weber, Ivo Rausch, Matthias Pones, Ingrid Simonitsch-Klupp, Leonhard Müllauer, Werner Dolak, Julius Lukas, Markus Raderer
Journal: Clinical Nuclear Medicine (2016)

To determine whether interim F-FDG PET or interim diffusion-weighted magnetic resonance imaging (DWI) can predict the end-of-treatment (EOT) outcome after immunotherapy in patients with FDG-avid extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT).Patients with untreated MALT lymphoma prospectively underwent whole-body F-FDG PET/CT and DWI before treatment (baseline), and after three cycles (interim) of rituximab-based immunotherapy. Maximum and mean standardized uptake values (SUVmax, SUVmean), and minimum and mean apparent diffusion coefficients (ADCmin, ADCmean), were measured for up to three target lesions per patient. Rates of change between baseline and interim examinations (ΔSUVmax, ΔSUVmean, ΔADCmin, and ΔADCmean) were compared, using ANOVAs, between the four end-of-treatment (EOT, after six cycles of immunotherapy) outcomes: complete remission (CR), partial remission (PR), stable disease (SD), or progressive disease (PD).Fifteen patients with 25 lesions were included. Lesion-based post hoc tests showed significant differences between CR and PR for ΔSUVmax (P < 0.001), ΔSUVmean (P < 0.001), and ΔADCmin (P = 0.044), and between CR and SD for ΔSUVmax (P < 0.001), ΔSUVmean (P < 0.001), ΔADCmin (P = 0.021), and ΔADCmean (P = 0.022). No lesion showed PD at EOT.Both quantitative interim F-FDG PET and interim DWI may possibly be useful to predict complete remission at end-of-treatment in MALT lymphoma patients after immunotherapy.
Prognostic value of the ratio of positive axillary lymph node after neoadjuvant chemotherapy in Peruvian patients with breast cancer.
Authors: T. Vidaurre, M. Calderón, R. Mantilla, C. E. Vigil, M. León, L. Más, M. Montanez, S. P. Neciosup, H. Gomez
Journal: Journal of Clinical Oncology (2011)

e11521 Background: The prognostic value of lymph node involvement after neoadjuvant chemotherapy for breast cancer is not straightforward. However, numerous studies suggest that nodal ratios (absolute number of involved nodes/number of nodes resected) may have greater prognostic value than absolute numbers of involved nodes. We evaluated whether lymph node involvement is associated with overall survival in patients with treated with neoadjuvant chemotherapy and whether lymph node ratio (LNR) is a superior prognosticator when compared to node status (TNM). Methods: Retrospective cohort of peruvian women with locally breast cancer who receiving neoadjuvant chemotherapy between 2004 and 2006 in the INEN. During that time trastuzumab was not available in our country. We evaluate the prognostic value of the LNR [low (>0 and <0.2), intermediate (0.2-0.65) and high risk (>0.65)] and N staging [N1, y N2 and N3] with multivariate Cox regression analysis. Results: 80 patients were included; we analyzed OS in 3 years. 53,9 was medium age. When using the LNR classification, 31 patients were categorized zero, 12 as low, 21 as intermediate and 16 as high risk. For classic N staging, 31 were N0, 10 N1, 8 N2 and 31 N3. Compared to the low risk category, LNR zero corresponded to an adjusted hazard ratio (HR) of 1.2 (95%CI, 0.3-5.1), intermediate risk LNR to a HR of 2.1 (0.5-9.2) and high risk LNR to a HR of 4.2 (1.1-16.6). But, the N0 category corresponded to a HR of 1.1 (0.2-5.9), N2 to a HR 1.0 (0.1-8.0) and N3 to a HR 3.1 (0.7-13.9) compared to N1 patients. Conclusions: LNR after neoadjuvant chemotherapy is prognostic overall survival in patients treated with neoadjuvant chemotherapy, and does seem to be superior to classic N staging.
Inhibition of the PI3K/AKT/mTOR Pathway in Solid Tumors
Authors: Patricia Mucci LoRusso
Journal: Journal of Clinical Oncology (2016)

The phosphoinositide 3-kinase (PI3K) pathway plays an integral role in many cellular processes and is frequently altered in cancer, contributing to tumor growth and survival. Small molecule inhibitors have been developed that target the three major nodes of this pathway: PI3K, AKT, and mammalian target of rapamycin. However, because oncogenic PI3K pathway activation is achieved in diverse, potentially redundant ways, the clinical efficacy of these inhibitors as monotherapies has, so far, been limited, despite demonstrating promising preclinical activity. Moreover, pathway activation is associated with resistance to other therapies; thus, in combination, PI3K pathway inhibitors could restore therapeutic sensitivity to these agents. To maximize therapeutic benefit, drug combinations and schedules must be explored to identify those with the highest efficacy and lowest toxicity overlap. In addition, defining appropriate patient subpopulations, for both monotherapy and drug combinations, will be important. However, identifying predictive biomarkers remains a challenge.
P1-114: Primary endobronchial and pulmonary mucosa-associated lymphoid tissue (MALT) lymphoma; clinical manifestation and radiographic features
Authors: Seiji Doi, Akitoshi Kinoshita, Takaya Ikeda, Eisuke Sasaki, Junji Tsurutani, Yoichi Nakamura, Hiroshi Soda, Shigeru Kohno
Journal: Journal of Thoracic Oncology (2007)